Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii

Infection and Immunity

Volumn 70, Issue 12, 2002, Pages 6606-6613

  Kedzierski, Lukasz ^a,c   Black, Casilda G ^a   Goschnick, Matthew W ^a   Stowers, Anthony W ^b   Coppel, Ross L ^a  

^a MONASH UNIVERSITY   (Australia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; EPIDERMAL GROWTH FACTOR; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNIZATION; INFECTION PREVENTION; MALARIA; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; FEMALE; IMMUNIZATION; MALARIA; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; PLASMODIUM YOELII; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS;

EID: 0036892169     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.12.6606-6613.2002     Document Type: Article

References (42)

1. Anders, R. F., P. E. Crewther, S. Edwards, M. Margetts, M. L. Matthew, B. Pollock, and D. Pye. 1998. Immunization with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16:240-247.
2. Black, C. G., L. Wang, A. R. Hibbs, E. Werner, and R. L. Coppel. 1999. Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum. Infect. Immun. 67:2075-2081.
3. Bojang, K. A., S. K. Obaro, U. D'Alessandro, S. Bennett, P. Langerock, G. A. Targett, and B. M. Greenwood. 1998. An efficacy trial of the malaria vaccine SPf66 in Gambian infants: Second year of follow-up. Vaccine 16:62-67.
4. Bouharoun-Tayoun, H., C. Oeuvray, F. Lunel, and P. Druilhe. 1995. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182:409-418.
5. Crewther, P. E., M. L. S. M. Matthew, R. H. Flegg, and R. F. Anders. 1996. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect. Immun. 64:3310-3317.
6. Dalton, J. P., S. McGonigle, T. P. Rolph, and S. J. Andrews. 1996. Induction of protective immunity in cattle against infection with Fasciola hepatica by vaccination with cathepsin L proteinases and with hemoglobin. Infect. Immun. 64:5066-5074.
7. Daly, T. M., and C. A. Long. 1995. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J. Immunol. 155:236-243.
8. Davis, C. G. 1990. The many faces of epidermal growth factor repeats. New Biol. 2:410-419.
9. Dodoo, D., T. G. Theander, J. A. Kurtzhals, K. Koram, E. Riley, B. D. Akanmori, F. K. Nkrumah, and L. Hviid. 1999. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect. Immun. 67:2131-2137.
10. Good, M. F., D. C. Kaslow, and L. H. Miller. 1998. Pathways and strategies for developing a malaria blood-stage vaccine. Annu. Rev. Immunol. 16:57-87.
11. + T cells. J. Immunol. 159:3400-3411.
12. Holder, A. A., and R. R. Freeman. 1981. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 294:361-364.
13. 19) variants secreted from Saccharomyces cerevisiae. Mol. Biochem. Parasitol. 63:283-289.
14. Kedzierski, L., C. G. Black, and R. L. Coppel. 2000. Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii. Mol. Biochem. Parasitol. 105:137-147.
15. Kedzierski, L., C. G. Black, and R. L. Coppel. 2000. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Infect. Immun. 68:6034-6037.
16. Kedzierski, L., C. G. Black, A. W. Stowers, M. W. Goschnick, D. C. Kaslow, and R. L. Coppel. 2001. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii. Vaccine 19:4661-4668.
17. Kester, K. E., D. G. Heppner, C. F. Ockenhouse, B. T. Hall, G. Voss, E. de Buyl, M. Van Handenhove, D. M. Gordon, U. Krzych, M.-C. Dubois, M. Delchambre, N. Tornieporth, L. Vigneron, W. R. Ballou, and J. Cohen. 2000. Double blind, randomized Phase I/IIa trial of SmithKline Beecham's candidate malaria vaccine RTS,S+TRAP and TRAP, p. 34. Molecular Approaches to Malaria, Lorne, Victoria, Australia.
18. Kester, K. E., D. A. McKinney, N. Tornieporth, C. F. Ockenhouse, D. G. Heppner, T. Hall, U. Krzych, M. Delchambre, G. Voss, M. G. Dowler, J. Palensky, J. Wittes, J. Cohen, and W. R. Ballou. 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183:640-647.
19. Lawrence, G., Q. Cheng, C. Reed, D. Taylor, A. Stowers, N. Cloonan, C. Rzepczyk, A. Smillie, K. Anderson, D. Pombo, A. Allworth, D. Eisen, R. Anders, and A. Saul. 2000. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 18:1925-1931.
20. Ling, I. T., S. A. Ogun, and A. A. Holder. 1994. Immunization against malaria with a recombinant protein. Parasite Immunol. 16:63-67.
21. Marshall, V. M., A. Silva, M. Foley, S. Cranmer, L. Wang, D. J. McColl, D. J. Kemp, and R. L. Coppel. 1997. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect. Immun. 65:4460-4467.
22. Marshall, V. M., T. Wu, and R. L. Coppel. 1998. Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum. Mol. Biochem. Parasitol. 94:13-25.
23. Masinde, G. L., D. J. Krogstad, D. M. Gordon, and P. E. Duffy. 1998. Immunization with SPf66 and subsequent infection with homologous and heterologous Plasmodium falciparum parasites. Am. J. Trop. Med. Hyg. 59:600-605.
24. Ockenhouse, C. F., P. F. Sun, D. E. Lanar, B. T. Wellde, B. T. Hall, K. Kester, J. A. Stoute, A. Magill, U. Krzych, L. Farley, R. A. Wirtz, J. C. Sadoff, D. C. Kaslow, S. Kumar, L. W. Church, J. M. Crutcher, B. Wizel, S. Hoffman, A. Lalvani, A. V. Hill, J. A. Tine, K. P. Guito, C. de Taisne, R. Anders, T. Horii, E. Paoletti, and W. R. Ballou. 1998. Phase I/Ila safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177:1664-1673.
25. 19 are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193:1403-1412.
26. Patarroyo, M. E., R. Amador, P. Clavijo, A. Moreno, F. Guzman, P. Romero, R. Tascon, A. Franco, L. A. Murillo, G. Ponton, and G. Trujillo. 1988. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332:158-161.
27. Patarroyo, M. E., P. Romero, M. L. Torres, P. Clavijo, A. Moreno, A. Martinez, R. Rodriguez, F. Guzman, and E. Cabezas. 1987. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328:629-632.
28. Piacenza, L., D. Acosta, I. Basmadjian, J. P. Dalton, and C. Carmona. 1999. Vaccination with cathepsin L proteinases and with leucine aminopeptidase induces high levels of protection against fascioliasis in sheep. Infect. Immun. 67:1954-1961.
29. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. V. Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282:2085-2088.
30. Qureshi, S. T., L. Lariviere, G. Leveque, S. Clermont, K. J. Moore, P. Gros, and D. Malo. 1999. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189:615-625.
31. Renia, L., I. T. Ling, M. Marussig, F. Miltgen, A. A. Holder, and D. Mazier. 1997. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect. Immun. 65:4419-4423.
32. Rotman, H. L., T. M. Daly, and C. A. Long. 1999. Plasmodium: Immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Exp. Parasitol. 91:78-85.
33. Saul, A., G. Lawrence, A. Smillie, C. M. Rzepczyk, C. Reed, D. Taylor, K. Anderson, A. Stowers, R. Kemp, A. Allworth, R. F. Anders, G. V. Brown, D. Pye, P. Schoofs, D. O. Irving, S. L. Dyer, G. C. Woodrow, W. R. Briggs, R. Reber, and D. Sturchler. 1999. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17:3145-3159.
34. Shi, Y. P., S. E. Hasnain, J. B. Sacci, B. P. Holloway, H. Fujioka, N. Kumar, R. Wohlhueter, S. L. Hoffman, W. E. Collins, and A. A. Lal. 1999. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl. Acad. Sci. USA 96:1615-1620.
35. Stanley, S. L., Jr. 1998. Malaria vaccines: Are seven antigens better than one? Lancet 352:1163-1164.
36. Stoute, J. A., K. E. Kester, U. Krzych, B. T. Wellde, T. Hall, K. White, G. Glenn, C. F. Ockenhouse, N. Garcon, R. Schwenk, D. E. Lanar, P. Sun, P. Momin, R. A. Wirtz, C. Golenda, M. Slaoui, G. Wortmann, C. Holland, M. Dowler, J. Cohen, and W. R. Ballou. 1998. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178:1139-1144.
37. Taylor, M. G., M. C. Huggins, F. Shi, J. Lin, E. Tian, P. Ye, W. Shen, C. G. Qian, B. F. Lin, and Q. D. Bickle. 1998. Production and testing of Schistosoma japonicum candidate vaccine antigens in the natural ovine host. Vaccine 16:1290-1298.
38. Tine, J. A., D. E. Lanar, D. M. Smith, B. T. Wellde, P. Schultheiss, L. A. Ware, E. B. Kauffman, R. A. Wirtz, C. De Taisne, G. S. N. Hui, S. P. Chang, P. Church, M. R. Hollingdale, D. C. Kaslow, S. L. Hoffman, K. P. Guito, W. R. Ballou, J. C. Sadoff, and E. Paoletti. 1996. NYVAC-Pf7: A poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64:3833-3844.
39. Urdaneta, M., A. Prata, C. J. Struchiner, C. E. Tosta, P. Tauil, and M. Boulos. 1998. Evaluation of SPf66 malaria vaccine efficacy in Brazil. Am. J. Trop. Med. Hyg. 58:378-385.
40. Wang, L., V. M. Marshall, and R. L. Coppel. 2002. Limited polymorphism of the vaccine candidate merozoite surface protein 4 of Plasmodium falciparum. Mol. Biochem. Parasitol. 120:301-303.
41. Wang, R., Y. Charoenvit, T. M. Daly, C. A. Long, G. Corradin, and S. L. Hoffman. 1996. Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine. Immunol. Lett. 53:83-93.
42. Wu, T., C. G. Black, L. Wang, A. R. Hibbs, and R. L. Coppel. 1999. Lack of sequence diversity in the gene encoding merozoite surface protein 5 of Plasmodium falciparum. Mol. Biochem. Parasitol. 103:243-250.